MindRank in Phase 3 trial with first AI-assisted new drug
Story summaryThe company was aiming for approval in the second half of 2028, paving the way for a market launch in 2029
Read at South China Morning PostOpens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.